FY2025 EPS Estimates for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Lifted by Analyst

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Stock analysts at Zacks Research upped their FY2025 earnings per share (EPS) estimates for Ironwood Pharmaceuticals in a report issued on Wednesday, June 26th. Zacks Research analyst R. Department now expects that the biotechnology company will earn $0.72 per share for the year, up from their previous forecast of $0.71. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.56 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals’ Q4 2025 earnings at $0.19 EPS and FY2026 earnings at $0.96 EPS.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.20). Ironwood Pharmaceuticals had a negative net margin of 254.41% and a negative return on equity of 28.45%. The firm had revenue of $74.90 million for the quarter, compared to analyst estimates of $105.75 million. During the same quarter in the previous year, the company earned $0.25 EPS. The company’s quarterly revenue was down 28.0% compared to the same quarter last year.

A number of other analysts have also recently weighed in on the company. Craig Hallum dropped their price target on Ironwood Pharmaceuticals from $18.00 to $14.00 and set a “buy” rating on the stock in a research report on Friday, May 10th. StockNews.com upgraded Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, June 18th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $18.40.

Ironwood Pharmaceuticals Trading Down 4.6 %

Shares of Ironwood Pharmaceuticals stock opened at $6.22 on Monday. The business’s 50 day simple moving average is $6.67 and its 200-day simple moving average is $9.65. The stock has a market capitalization of $973.62 million, a price-to-earnings ratio of -0.92 and a beta of 0.52. Ironwood Pharmaceuticals has a twelve month low of $5.47 and a twelve month high of $15.70.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. First Eagle Investment Management LLC boosted its stake in Ironwood Pharmaceuticals by 11.1% during the 4th quarter. First Eagle Investment Management LLC now owns 907,225 shares of the biotechnology company’s stock valued at $10,379,000 after purchasing an additional 90,636 shares in the last quarter. Eventide Asset Management LLC bought a new stake in shares of Ironwood Pharmaceuticals during the 4th quarter worth $8,472,000. Walleye Capital LLC bought a new stake in shares of Ironwood Pharmaceuticals during the 3rd quarter worth $1,608,000. Norges Bank bought a new stake in shares of Ironwood Pharmaceuticals during the 4th quarter worth $9,321,000. Finally, 13D Management LLC boosted its stake in shares of Ironwood Pharmaceuticals by 971.8% during the 4th quarter. 13D Management LLC now owns 367,649 shares of the biotechnology company’s stock worth $4,206,000 after acquiring an additional 333,348 shares in the last quarter.

Insider Activity at Ironwood Pharmaceuticals

In related news, Director Julie Mchugh sold 22,766 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $6.29, for a total value of $143,198.14. Following the sale, the director now directly owns 139,528 shares in the company, valued at approximately $877,631.12. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Ironwood Pharmaceuticals news, Director Catherine Moukheibir sold 44,426 shares of the stock in a transaction on Thursday, June 6th. The stock was sold at an average price of $6.36, for a total transaction of $282,549.36. Following the completion of the transaction, the director now directly owns 84,207 shares of the company’s stock, valued at approximately $535,556.52. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Julie Mchugh sold 22,766 shares of the stock in a transaction on Monday, June 10th. The shares were sold at an average price of $6.29, for a total value of $143,198.14. Following the transaction, the director now directly owns 139,528 shares of the company’s stock, valued at $877,631.12. The disclosure for this sale can be found here. 12.90% of the stock is owned by insiders.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.